These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15620562)

  • 41. Factors associated with the pricing of childhood vaccines in the U.S. public sector.
    Chen W; Messonnier M; Zhou F
    Health Econ; 2018 Feb; 27(2):252-265. PubMed ID: 28660666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First countries to be recipients of GAVI funds.
    Maurice J
    Bull World Health Organ; 2000; 78(12):1477-8. PubMed ID: 11196504
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New vaccine adoption in lower-middle-income countries.
    Makinen M; Kaddar M; Molldrem V; Wilson L
    Health Policy Plan; 2012 May; 27 Suppl 2():ii39-49. PubMed ID: 22513731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Global harmonisation in vaccine price.
    Lancet Infect Dis; 2015 Mar; 15(3):249. PubMed ID: 25749216
    [No Abstract]   [Full Text] [Related]  

  • 46. [Vaccines: producers in countries of the Southern hemisphere].
    Bertrand JJ
    Med Trop (Mars); 2007 Aug; 67(4):347-50. PubMed ID: 17926792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi.
    Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F
    Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving access to vaccines through tiered pricing.
    Berkley S
    Lancet; 2014 Jun; 383(9936):2265-7. PubMed ID: 24636625
    [No Abstract]   [Full Text] [Related]  

  • 51. Policy analysis: an essential research tool for the introduction of vaccines in developing countries.
    Mahoney R
    J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching costs in competitive health insurance markets: The role of insurers' pricing strategies.
    Lamiraud K; Stadelmann P
    Health Econ; 2020 Sep; 29(9):992-1012. PubMed ID: 32542729
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Social welfare and adolescent vaccination programs in the United States: the economic opportunities for a systematic expansion.
    Vernon JA; Payette M; Chatterjee A
    Soc Work Public Health; 2009; 24(5):414-45. PubMed ID: 19731186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A learning experience from price negotiations for vaccines.
    Teerawattananon Y; Tritasavit N
    Vaccine; 2015 May; 33 Suppl 1():A11-2. PubMed ID: 25919150
    [No Abstract]   [Full Text] [Related]  

  • 57. Pricing strategy for aesthetic surgery: economic analysis of a resident clinic's change in fees.
    Krieger LM; Shaw WW
    Plast Reconstr Surg; 1999 Feb; 103(2):695-700. PubMed ID: 9950562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement and pricing of risk in insurance markets.
    Tsanakas A; Desli E
    Risk Anal; 2005 Dec; 25(6):1653-68. PubMed ID: 16506990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Setting prices for new vaccines (in advance).
    McGuire TG
    Int J Health Care Finance Econ; 2003 Sep; 3(3):207-24. PubMed ID: 14626000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.